Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Tuberculosis

Free Subscription Articles published in Int J Tuberc Lung Dis Retrieve available abstracts of 295 articles: HTML format

Single Articles

January 2026
1. PELODAN MEP, Tavares RBV, Vigato BF, Bernardi WOB, et al
   TB screening and prevention in migrants, refugees, and stateless populations in the Global South.
   Int J Tuberc Lung Dis. 2026;30:1-3.
   PubMed     Abstract available
   
   
   
2. COLICHI RMB, Ferreira Filho SP, Alves RC, Lima SAM, et al
   TB diagnosis: patent registers analysis in Brazil.
   Int J Tuberc Lung Dis. 2026;30:11-15.
   PubMed     Abstract available
   
   
   
3. ANAND PK, Patel D, Lata S, Gautam JK, et al
   Factors associated with pulmonary TB in malnourished children admitted to rehabilitation centres.
   Int J Tuberc Lung Dis. 2026;30:21-26.
   PubMed     Abstract available
   
   
   
4. DUMA ST, Dalmat R, Magcaba Z, Niu X, et al
   Performance of C-reactive protein, haemoglobin, and albumin as TB/HIV triage tests in hospitalised adults.
   Int J Tuberc Lung Dis. 2026;30:4-10.
   PubMed     Abstract available
   
   
   
5. LAGASON GAA, Gler MT, Ganaden JAR, Panganiban KA, et al
   Undernutrition assessment and nutrient intake of people with TB in the Philippines.
   Int J Tuberc Lung Dis. 2026;30:16-20.
   PubMed     Abstract available
   
   
   
6. AKTER S, Khan MAS, Bin Zahur SM, Jahan D, et al
   Factors associated with initiation of TB preventive therapy.
   Int J Tuberc Lung Dis. 2026;30:27-33.
   PubMed     Abstract available
   
   
   September 2025
7. HARRIES AD, Kumar AMV, Nair D, Satyanarayana S, et al
   Operational research to End TB: 2(nd) edition of the Union's Guide to operational research.
   Int J Tuberc Lung Dis. 2025;29:431-433.
   PubMed     Abstract available
   
   
   
8. CASTELLINO LM, Nguyen S, Cobb S, Sreeramoju PV, et al
   Identifying MTB-exposed homeless persons with an electronic health record alert: a safety-net health system's experience.
   Int J Tuberc Lung Dis. 2025;29:441-446.
   PubMed     Abstract available
   
   
   
9. SHARMA S, Patankar S, Becerra MC, Bhalla M, et al
   Yield of a contact investigation among children living with drug-resistant TB patients.
   Int J Tuberc Lung Dis. 2025;29:455-461.
   PubMed     Abstract available
   
   
   
10. PERUMAL R, Pillay S, Bagratee N, Tulsi J, et al
    Anatomical and functional characteristics of symptomatic post-TB lung disease.
    Int J Tuberc Lung Dis. 2025;29:434-440.
    PubMed     Abstract available
    
    
    
11. SINGH S, Boorgula GD, Galvez RA, Heysell SK, et al
    Mycobacteria susceptibility to epetraborole: how far can it go?
    Int J Tuberc Lung Dis. 2025;29:447-454.
    PubMed     Abstract available
    
    
    
12. KODAMA T, Sasaki Y, Tsuyuguchi K, Okumura M, et al
    Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2025;29:462-468.
    PubMed     Abstract available
    
    
    August 2025
13. MALIK AA, Martinez L
    Achieving optimal uptake of TB preventive treatment for rifampin-resistant and/or multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2025;29:387-389.
    PubMed     Abstract available
    
    
    
14. ZHOU M, Yang Z, Ni Z, Xiao J, et al
    Clinical outcomes for drug-resistant TB patients after adjunctive resectional lung surgery.
    Int J Tuberc Lung Dis. 2025;29:397-403.
    PubMed     Abstract available
    
    
    
15. PRASETYO YA, Thanasilp S, Preechawong S
    The development of an adherence to treatment scale for pulmonary TB.
    Int J Tuberc Lung Dis. 2025;29:410-415.
    PubMed     Abstract available
    
    
    
16. NGIAM JN, Koh MCY, D'Ambrosio L, Goletti D, et al
    Artificial intelligence for TB education and counselling: a modified Delphi consensus.
    Int J Tuberc Lung Dis. 2025;29:390-396.
    PubMed     Abstract available
    
    
    
17. SCHRAUFNAGEL AM, Crowder R, Wambi P, Nakasendwa S, et al
    Use of a digital adherence technology to support TB treatment among adolescents.
    Int J Tuberc Lung Dis. 2025;29:404-409.
    PubMed     Abstract available
    
    
    
18. DAS M, Kalra A, ThekkePurakkal AS, Showket T, et al
    Implementing TB preventive therapy: lessons from a large-scale initiative in India.
    Int J Tuberc Lung Dis. 2025;29:416-421.
    PubMed     Abstract available
    
    
    
19. ZENNER D, Oyebode O, Russo G, Samuels F, et al
    Global blind spots in TB control - the need to focus on deprived urban neighbourhoods.
    Int J Tuberc Lung Dis. 2025;29:337-339.
    PubMed     Abstract available
    
    
    
20. DEY D, Bhattacharyya P, Roy D, Saha D, et al
    Does childhood TB or pneumonia impact COPD or asthma in adulthood?
    Int J Tuberc Lung Dis. 2025;29:349-354.
    PubMed     Abstract available
    
    
    
21. RESENDIZ-GALVAN JE, Murphy RA, Govender T, Teponnou GAK, et al
    Model-based evaluation of adherence to bedaquiline and clofazimine in adults with drug-resistant TB.
    Int J Tuberc Lung Dis. 2025;29:362-369.
    PubMed     Abstract available
    
    
    
22. TIBERI S, Akkerman O, Sotgiu G, Saderi L, et al
    Drug management of TB in the intensive care setting: an international multicentre study.
    Int J Tuberc Lung Dis. 2025;29:340-348.
    PubMed     Abstract available
    
    
    
23. MOLLALIGN H, Beyene D, Moga S, Alemayehu DH, et al
    Mycobacterium tuberculosis genotypes isolated from clinical specimens of extrapulmonary TB.
    Int J Tuberc Lung Dis. 2025;29:355-361.
    PubMed     Abstract available
    
    
    
24. MPUNGA J, Mbendera K, Mwenyenkulu T, Chirwa S, et al
    Feasibility of stool-based GeneXpert for the diagnosis of pulmonary TB in children.
    Int J Tuberc Lung Dis. 2025;29:370-374.
    PubMed     Abstract available
    
    
    June 2025
25. NYILANA H, Reis K, Seepamore B, Perumal R, et al
    Experiences of key populations in multidrug-resistant TB and HIV.
    Int J Tuberc Lung Dis. 2025;29:289-292.
    PubMed     Abstract available
    
    
    
26. DELMAS V, Vasiliu A, Tchakounte Youngui B, Ssekyanzi B, et al
    Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children.
    Int J Tuberc Lung Dis. 2025;29:312-317.
    PubMed     Abstract available
    
    
    
27. VISCA D, Centis R, D'Ambrosio L, Spanevello A, et al
    Evaluating the impact of COVID-19 or SARS-CoV-2 vaccination on TB infection testing in the context of TB elimination.
    Int J Tuberc Lung Dis. 2025;29:293-298.
    PubMed     Abstract available
    
    
    
28. CROWDER R, Nakasendwa S, Kityamuwesi A, Musoke M, et al
    Scale-up of 99DOTS for TB treatment supervision: an interrupted time series analysis.
    Int J Tuberc Lung Dis. 2025;29:306-311.
    PubMed     Abstract available
    
    
    
29. GALVIS ME, Gao GE, Salerno MM, Whitehead M, et al
    Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen.
    Int J Tuberc Lung Dis. 2025;29:318-324.
    PubMed     Abstract available
    
    
    May 2025
30. AFIFAH NN, Intania R, Wijaya I, Obinata H, et al
    The interplay between TB and lung cancer: risk, prognosis and treatment dynamics.
    Int J Tuberc Lung Dis. 2025;29:243-252.
    PubMed     Abstract available
    
    
    
31. DONKENG DONFACK VF, Ninkeh Nono V, Napa Tchuedji YLG, Ongboulal SM, et al
    Performances of loop-mediated isothermal amplification for TB diagnosis in children.
    Int J Tuberc Lung Dis. 2025;29:259-264.
    PubMed     Abstract available
    
    
    
32. CHANI K, Athallah MA, Colquhoun S, Tsheten T, et al
    Proportions of Xpert MTB/RIF Ultra 'trace' results vary widely among different populations with presumptive TB.
    Int J Tuberc Lung Dis. 2025;29:271-277.
    PubMed     Abstract available
    
    
    
33. MUSAAZI J, Sekaggya-Wiltshire C, Zawedde-Muyanja S, Kalema N, et al
    TB incidence following accelerated TB preventive treatment scale-up campaigns in Uganda.
    Int J Tuberc Lung Dis. 2025;29:253-258.
    PubMed     Abstract available
    
    
    
34. TABACKMAN A, Gupte AN, Thangakunam B, Babu SP, et al
    Impact of premorbid nutritional status on TB severity.
    Int J Tuberc Lung Dis. 2025;29:265-270.
    PubMed     Abstract available
    
    
    
35. MIN J, Park JE, Kim SY, Kim YY, et al
    Disability is a risk factor for 1-year mortality after TB diagnosis.
    Int J Tuberc Lung Dis. 2025;29:207-213.
    PubMed     Abstract available
    
    
    
36. CHE B, Peng Y, Zheng X, Chen B, et al
    Attrition in the treatment cascade among elderly patients with multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2025;29:218-226.
    PubMed     Abstract available
    
    
    
37. SCHIUMA M, Colaneri M, Cattaneo D, Fusi M, et al
    Rifampicin drug monitoring in TB patients: new evidence for increased dosage?
    Int J Tuberc Lung Dis. 2025;29:202-206.
    PubMed     Abstract available
    
    
    
38. MCNALLY G, Solomon D, Brown M, Capocci S, et al
    A diagnostic certainty score to support improvements in culture confirmation of TB.
    Int J Tuberc Lung Dis. 2025;29:227-230.
    PubMed     Abstract available
    
    
    March 2025
39. CAO J, Shao G, Zhong H, Davies Forsman L, et al
    Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes.
    Int J Tuberc Lung Dis. 2025;29:164-170.
    PubMed     Abstract available
    
    
    
40. MULEBEKE R, Chemutai C, Mubangizi I, Balina M, et al
    Effect of community awareness, screening, diagnosis, and treatment campaigns on TB care in Uganda.
    Int J Tuberc Lung Dis. 2025;29:178-183.
    PubMed     Abstract available
    
    
    
41. ZAVALA S, Kiritsy MC, Cox GM, Ahmed A, et al
    Geographic information systems analysis to focus TB screening among people born in endemic countries.
    Int J Tuberc Lung Dis. 2025;29:159-163.
    PubMed     Abstract available
    
    
    
42. NASIRI MJ, Khoshdel N, Venketaraman V
    Glutathione and N-acetylcysteine in TB management.
    Int J Tuberc Lung Dis. 2025;29:171-177.
    PubMed     Abstract available
    
    
    
43. NABITY SA, Moffitt AD, Mponda K, Melgar M, et al
    Urine metabolite-determined isoniazid adherence under programmatic conditions in people living with HIV.
    Int J Tuberc Lung Dis. 2025;29:97-102.
    PubMed     Abstract available
    
    
    
44. TRAN HT, Nguyen CT, Nguyen HT, Godin I, et al
    Validation of a questionnaire to screen chronic obstructive respiratory diseases.
    Int J Tuberc Lung Dis. 2025;29:113-118.
    PubMed     Abstract available
    
    
    
45. PONTICIELLO MN, Nanziri LM, Hennein R, Ochom E, et al
    Adaptation and validation of perceived HIV and TB stigma scales among persons with TB.
    Int J Tuberc Lung Dis. 2025;29:127-134.
    PubMed     Abstract available
    
    
    
46. TRAM KH, Ong'ang'o J, Kiplimo R, Hawn TR, et al
    Mobility patterns, activity locations, and TB in Nairobi, Kenya.
    Int J Tuberc Lung Dis. 2025;29:103-112.
    PubMed     Abstract available
    
    
    
47. PRIKHODCHENKO O, Arbuzova Y, Serikbayeva K, Zhakhina G, et al
    Epidemiology, detection, diagnosis and treatment of TB in children in Kazakhstan.
    Int J Tuberc Lung Dis. 2025;29:135-140.
    PubMed     Abstract available
    
    
    February 2025
48. BOUZOUITA I, Cabibbe AM, Ghariani A, Smaoui S, et al
    First report of multidrug-resistant M. tuberculosis Beijing strain isolated from the indigenous population in Tunisia.
    Int J Tuberc Lung Dis. 2025;29:92-94.
    PubMed    
    
    
    
49. LEGRAND KE, Allel K, Khan P, Hayes RJ, et al
    Contamination effects in cluster randomised trials of TB interventions.
    Int J Tuberc Lung Dis. 2025;29:47-53.
    PubMed     Abstract available
    
    
    
50. MWANZA W, Lutinala M, Mundia K, Klinkenberg E, et al
    Stool-based Xpert testing for diagnosis of TB in children and critically ill adults.
    Int J Tuberc Lung Dis. 2025;29:75-79.
    PubMed     Abstract available
    
    
    
51. NGUENHA D, Ndebele F, Saavedra B, Mambuque E, et al
    BMI as a predictor of progression from TB infection to active TB in PLHIV.
    Int J Tuberc Lung Dis. 2025;29:54-59.
    PubMed     Abstract available
    
    
    
52. TCHAKOUNTE YOUNGUI B, Tchounga BK, Atwine D, Vasiliu A, et al
    Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention.
    Int J Tuberc Lung Dis. 2025;29:67-74.
    PubMed     Abstract available
    
    
    
53. ISLAM MN, Khan MK, Hassan J, Nahar MS, et al
    Reversible zoonotic transmission of TB from humans to dairy cattle.
    Int J Tuberc Lung Dis. 2025;29:80-87.
    PubMed     Abstract available
    
    
    January 2025
54. AYALEW S, Wegayehu T, Wondale B, Alemayehu DH, et al
    Multigene Mycobacterium tuberculosis cell-free DNA assay.
    Int J Tuberc Lung Dis. 2025;29:13-19.
    PubMed     Abstract available
    
    
    
55. MUZANYI G, Ntale M, Salata R, Joloba M, et al
    Hair isoniazid levels predict TB sputum culture conversion.
    Int J Tuberc Lung Dis. 2025;29:1-6.
    PubMed     Abstract available
    
    
    
56. PRATHIKSHA G, Newtonraj A, Thiruvengadam K, Frederick A, et al
    TB prevalence is higher among smokers.
    Int J Tuberc Lung Dis. 2025;29:29-34.
    PubMed     Abstract available
    
    
    December 2024
57. AFAQ S
    A comprehensive person-centred TB care model, from malnutrition to mental health.
    Int J Tuberc Lung Dis. 2024;28:561-563.
    PubMed     Abstract available
    
    
    
58. SRIVASTAVA S, Gumbo T
    Examining effective monotherapy hypothesis for TB therapy failure and resistance emergence.
    Int J Tuberc Lung Dis. 2024;28:572-577.
    PubMed     Abstract available
    
    
    
59. ALATISE MA, Narasimhan P, Gbadamosi MD, Chughtai AA, et al
    Accessibility and TB patient satisfaction in Nigeria.
    Int J Tuberc Lung Dis. 2024;28:585-591.
    PubMed     Abstract available
    
    
    
60. ROSS J, Cummings MJ, Bakamutumaho B, Tokarz R, et al
    Xpert MTB/RIF Ultra enables sensitive detection of Mycobacterium tuberculosis in blood.
    Int J Tuberc Lung Dis. 2024;28:594-596.
    PubMed    
    
    
    November 2024
61. ENGEL N, Apolosi I, Bhargava A, Bhan A, et al
    Building social equity and person-centred innovation into the end TB response.
    Int J Tuberc Lung Dis. 2024;28:517-520.
    PubMed     Abstract available
    
    
    
62. SHAPIRO AN, Scott L, Moultrie H, Jacobson KR, et al
    Risk factors for and timing of presumptive recurrent TB.
    Int J Tuberc Lung Dis. 2024;28:527-533.
    PubMed     Abstract available
    
    
    
63. LIN CM, Chen YL, Cheng YF, Cheng CY, et al
    Clinical characteristics and decortication outcomes of bacterial, tuberculous and fungal pleural infection.
    Int J Tuberc Lung Dis. 2024;28:541-546.
    PubMed     Abstract available
    
    
    
64. CHAPMAN HEDGES KN, Scott N, Belknap R, Goldberg SV, et al
    Reasons for acceptance or nonparticipation in iAdhere: a trial of latent TB infection treatment.
    Int J Tuberc Lung Dis. 2024;28:521-526.
    PubMed     Abstract available
    
    
    
65. PALMER M, van der Zalm MM, Schaaf HS, Goussard P, et al
    Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial.
    Int J Tuberc Lung Dis. 2024;28:547-553.
    PubMed     Abstract available
    
    
    October 2024
66. MALDARI A, Brigham M, Emeto TI, Adegboye O, et al
    The impact of the COVID-19 pandemic on TB in a low TB burden setting.
    Int J Tuberc Lung Dis. 2024;28:510-512.
    PubMed    
    
    
    
67. VANLEEUW L, Sanchez M, Forse R, Zembe-Mkabile W, et al
    Making social protection a reality for people with TB: a perspective on new global guidance.
    Int J Tuberc Lung Dis. 2024;28:473-475.
    PubMed     Abstract available
    
    
    
68. RICCARDI N, Monari C, Antonello RM, Saderi L, et al
    TB outpatient care in a high-income, low-incidence country.
    Int J Tuberc Lung Dis. 2024;28:513-515.
    PubMed    
    
    
    
69. LARSSON L, Corbett C, Kalmambetova G, Utpatel C, et al
    Whole-genome sequencing drug susceptibility testing is associated with positive MDR-TB treatment response.
    Int J Tuberc Lung Dis. 2024;28:494-499.
    PubMed     Abstract available
    
    
    
70. KODAMA T, Chikamatsu K, Kamada K, Mizuno K, et al
    Evaluation of testing face-mask filter samples with LAMP shows high rates of detection in pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:476-481.
    PubMed     Abstract available
    
    
    
71. COLOMB S, Tricot M, Baccino E, Lesage FX, et al
    Occupational transmission of TB infection during autopsy.
    Int J Tuberc Lung Dis. 2024;28:508-509.
    PubMed    
    
    
    
72. MARTINS MF, Dauphinais MR, Tabackman A, Narasimhan PB, et al
    Clearing the air: microcosting the carbon impact of drug-susceptible pulmonary TB treatment.
    Int J Tuberc Lung Dis. 2024;28:488-493.
    PubMed     Abstract available
    
    
    
73. SMIRNOVA N, Bryan CS, Salindri AD, Avaliani T, et al
    Cavitary lung lesions and quality of life after TB.
    Int J Tuberc Lung Dis. 2024;28:505-507.
    PubMed    
    
    
    September 2024
74. CEVIK M, Sturdy A, Maraolo AE, Dekkers BGJ, et al
    A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs.
    Int J Tuberc Lung Dis. 2024;28:454-460.
    PubMed     Abstract available
    
    
    
75. MARAIS BJ, Buck WC, Schaaf HS
    The hidden burden of miliary TB in children and adolescents.
    Int J Tuberc Lung Dis. 2024;28:407-409.
    PubMed    
    
    
    
76. DECKER SR, Marchesan LQ, Silva DW, Deutschendorf C, et al
    A cohort study exploring variables associated with mortality in critically ill TB patients.
    Int J Tuberc Lung Dis. 2024;28:461-463.
    PubMed    
    
    
    
77. BUONSENSO D, Mariani F, Morello R, Song R, et al
    Miliary TB in children and adolescents: a scoping review.
    Int J Tuberc Lung Dis. 2024;28:412-418.
    PubMed     Abstract available
    
    
    
78. NGUYEN LN, Phan PT, Jaramillo E, Dinh A, et al
    Respiratory impairment after completion of TB treatment: a neglected but vitally important issue.
    Int J Tuberc Lung Dis. 2024;28:410-411.
    PubMed    
    
    
    
79. AGUIAR A, Abreu M, Gaio R, Duarte R, et al
    Barriers to TB detection in Portuguese prisons.
    Int J Tuberc Lung Dis. 2024;28:464-466.
    PubMed    
    
    
    
80. BIEWER A, Tintaya K, Roman B, Hurwitz S, et al
    Diagnostic accuracy of an exhaled breath test for TB in hospitalized patients with cough or risk.
    Int J Tuberc Lung Dis. 2024;28:446-453.
    PubMed     Abstract available
    
    
    
81. ZAWEDDE J, Abelman R, Musisi E, Nyabigambo A, et al
    Lung function and health-related quality of life among adult patients following pulmonary TB treatment.
    Int J Tuberc Lung Dis. 2024;28:419-426.
    PubMed     Abstract available
    
    
    
82. ARMSTRONG-HOUGH M, Shelby T, Ggita J, Nangendo J, et al
    An adapted scale to measure perceived TB and HIV stigma during household contact investigation.
    Int J Tuberc Lung Dis. 2024;28:433-438.
    PubMed     Abstract available
    
    
    
83. TAKEDA K, Nagai H, Kawashima M, Kosai I, et al
    Cold temperatures during sample transportation may cause false-negative interferon-gamma release assays used to diagnose TB infection.
    Int J Tuberc Lung Dis. 2024;28:467-469.
    PubMed    
    
    
    August 2024
84. HOOLE AS, Ilyas A, Munawar S, Cant M, et al
    Post-TB bronchiectasis: clinical characteristics and microbiology.
    Int J Tuberc Lung Dis. 2024;28:405-406.
    PubMed    
    
    
    
85. JASWAL MR, Farooq S, Hussain H, Shah J, et al
    TB disease yield from household contact screening of TB index patients in Pakistan.
    Int J Tuberc Lung Dis. 2024;28:374-380.
    PubMed     Abstract available
    
    
    
86. KLAOS K, Agejeva A, Hurt K, Kummik T, et al
    Prospective evaluation of thin-layer agar colour test in routine diagnosis of multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2024;28:387-394.
    PubMed     Abstract available
    
    
    
87. DAHL VN, Butova T, Kuzhko M, Sapelnik N, et al
    HIV remains a deadly companion to drug-resistant TB in Ukraine.
    Int J Tuberc Lung Dis. 2024;28:400-402.
    PubMed    
    
    
    
88. DENHOLM JT, Coussens A, Houben RMGJ, Horton KC, et al
    The International Consensus for Early TB framework (ICE-TB): Implications from a low-incidence setting.
    Int J Tuberc Lung Dis. 2024;28:381-386.
    PubMed     Abstract available
    
    
    
89. SIERRA CJ, Huang Y, Cotton SA, Hughes TD, et al
    Clinical outcomes in comorbid COVID-19 and TB cases.
    Int J Tuberc Lung Dis. 2024;28:397-399.
    PubMed    
    
    
    July 2024
90. DYTKO O, Park M, Nicholas R, Akshikar R, et al
    Digital surveillance of ocular toxicity during TB treatment.
    Int J Tuberc Lung Dis. 2024;28:360-361.
    PubMed    
    
    
    
91. HAPPAERTS M, Lorent N, Andre E
    Exploring the use of exhaled breath as a diagnostic tool for pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:317-321.
    PubMed     Abstract available
    
    
    
92. LO HY, Huang YC, Chan PC, Lee CC, et al
    TB notifications among citizens and non-citizens in Taiwan.
    Int J Tuberc Lung Dis. 2024;28:328-334.
    PubMed     Abstract available
    
    
    
93. SEMAKULA L, Kakai I, Zawedde-Muyanja S, Nerima P, et al
    Private pharmacy and community health worker engagement in the provision of TB services.
    Int J Tuberc Lung Dis. 2024;28:343-347.
    PubMed     Abstract available
    
    
    
94. GODEFROY N, Monsel G, Jaureguiberry S, Henry B, et al
    Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB.
    Int J Tuberc Lung Dis. 2024;28:357-359.
    PubMed    
    
    
    
95. SAVINKINA A, Muyindike W, Hahn JA, Emenyonu NI, et al
    Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol.
    Int J Tuberc Lung Dis. 2024;28:335-342.
    PubMed     Abstract available
    
    
    
96. PRATHIKSHA G, Selvaraju S, Thiruvengadam K, Frederick A, et al
    Programmatic implications of a sub-national TB prevalence survey in India.
    Int J Tuberc Lung Dis. 2024;28:348-353.
    PubMed     Abstract available
    
    
    June 2024
97. MIN J, Kim SY, Park JE, Park JH, et al
    Did public-private partnerships reduce TB incidence in Korea?
    Int J Tuberc Lung Dis. 2024;28:306-308.
    PubMed    
    
    
    
98. CHIANG SS, Jenkins HE
    Pediatric TB treatment outcomes: targets for improvement.
    Int J Tuberc Lung Dis. 2024;28:263-265.
    PubMed    
    
    
    
99. DIAS JV, Varandas L, Goncalves L, Kagina B, et al
    Outcomes of childhood TB in countries with a universal BCG vaccination policy.
    Int J Tuberc Lung Dis. 2024;28:273-277.
    PubMed     Abstract available
    
    
    
100. KIWANUKA N, Quach T, Kakaire R, Zalwango S, et al
     Incidence of tuberculous infection in a TB-endemic city.
     Int J Tuberc Lung Dis. 2024;28:266-272.
     PubMed     Abstract available
     
     
     
101. PHELAN JE, Utpatel C, Ismail N, Cortes T, et al
     Careful classification of potential bedaquiline resistance mutations is critical when analysing their clinical impact.
     Int J Tuberc Lung Dis. 2024;28:312-313.
     PubMed    
     
     
     
102. CARVALHO MM, Barbosa P, Ramos P, Vieira M, et al
     Limitations of using tuberculin skin test to screen for TB in patients with psoriasis.
     Int J Tuberc Lung Dis. 2024;28:304-305.
     PubMed    
     
     
     
103. RAMOS-RINCON JM, Montoya B, Simpson G, Burgos M, et al
     An epidemiological analysis of TB trends in native and migrant populations, New Mexico, 1993-2021.
     Int J Tuberc Lung Dis. 2024;28:278-286.
     PubMed     Abstract available
     
     
     
104. SHEARER K, Variava E, Kekana B, Abraham P, et al
     TB diagnoses and mortality in hospitalized people living with HIV in South Africa.
     Int J Tuberc Lung Dis. 2024;28:301-303.
     PubMed    
     
     
     
105. WORDUI S, Masu A, Golden L, Chaya S, et al
     Aetiology of pleural effusions in children living in a high TB endemic setting.
     Int J Tuberc Lung Dis. 2024;28:295-300.
     PubMed     Abstract available
     
     
     
106. BONGOMIN F, Denning DW
     Chronic pulmonary aspergillosis: a neglected post-TB lung disease.
     Int J Tuberc Lung Dis. 2024;28:314-315.
     PubMed    
     
     
     May 2024
107. PATEL MA, Durovni B, Salazar-Austin N, Cavalcante SC, et al
     TB prevalence among pregnant women with HIV in Rio de Janeiro, Brazil.
     Int J Tuberc Lung Dis. 2024;28:259-261.
     PubMed    
     
     
     
108. ALLAN-BLITZ LT, Yarbrough C, Ndayizigiye M, Wade C, et al
     Point-of-care ultrasound for diagnosing extrapulmonary TB.
     Int J Tuberc Lung Dis. 2024;28:217-224.
     PubMed     Abstract available
     
     
     
109. RAUTMAN LH, Kammerer JS, Silk BJ, Marconi VC, et al
     Characteristics of TB cases without documented sputum culture in the United States, 2011-2021.
     Int J Tuberc Lung Dis. 2024;28:231-236.
     PubMed     Abstract available
     
     
     
110. MANGAN JM, Hedges KNC, Salerno MM, Tatum K, et al
     Facilitators and barriers to adolescent participation in a TB clinical trial.
     Int J Tuberc Lung Dis. 2024;28:243-248.
     PubMed     Abstract available
     
     
     
111. WADEMAN DT, Saule Z, Marthinus A, Viljoen L, et al
     Acceptability of clofazimine capsules in children and adolescents with rifampicin-resistant TB.
     Int J Tuberc Lung Dis. 2024;28:256-258.
     PubMed    
     
     
     
112. DIAZ YDG, Palma D, Vargas-Leguas H, Rodrigo T, et al
     Factors associated with referrals for directly observed treatment and unsuccessful treatment.
     Int J Tuberc Lung Dis. 2024;28:237-242.
     PubMed     Abstract available
     
     
     
113. MARQUES MS, Silva T, Gomes A, Pereira C, et al
     Factors associated with patient delay in the diagnosis of TB - a study of health-seeking behaviour.
     Int J Tuberc Lung Dis. 2024;28:249-252.
     PubMed    
     
     
     April 2024
114. PARREIRA PL, Fonseca AU, Soares F, Conte MB, et al
     Chest X-ray evaluation using machine learning to support the early diagnosis of pulmonary TB.
     Int J Tuberc Lung Dis. 2024;28:171-175.
     PubMed     Abstract available
     
     
     
115. DOGO FM, Ate S, Agossou K, Menon S, et al
     Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo.
     Int J Tuberc Lung Dis. 2024;28:195-201.
     PubMed     Abstract available
     
     
     
116. ILAIWY G, Heysell SK, Lukumay S, Agustino D, et al
     Cash transfers to enhance completion of TB screening among household contacts in rural Tanzania.
     Int J Tuberc Lung Dis. 2024;28:176-182.
     PubMed     Abstract available
     
     
     
117. MARKS SM, Winston CA
     Estimated treatment costs for multidrug-resistant TB in the United States.
     Int J Tuberc Lung Dis. 2024;28:214-215.
     PubMed    
     
     
     
118. KAWATSU L, Uchimura K, Schwalb A, Houben R, et al
     New perspectives on the secular trend in pulmonary TB in post-war Japan (1953-1980).
     Int J Tuberc Lung Dis. 2024;28:207-209.
     PubMed    
     
     
     
119. SHAIKH A, Sriraman K, Vaswani S, Shah I, et al
     SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB.
     Int J Tuberc Lung Dis. 2024;28:189-194.
     PubMed     Abstract available
     
     
     March 2024
120. OTA M, Hirao S, Uchimura K
     Lower TB notification rates in later life in the same birth cohort, Japan, 1950-2020.
     Int J Tuberc Lung Dis. 2024;28:157-159.
     PubMed    
     
     
     
121. PONTALI E, Akkerman OW, Zenner D, Migliori GB, et al
     Post-TB lung disease: keep going beyond TB!
     Int J Tuberc Lung Dis. 2024;28:113-114.
     PubMed    
     
     
     
122. THEKKUR P, Thiagesan R, Nair D, Karunakaran N, et al
     Using timeliness metrics for household contact tracing and TB preventive therapy in the private sector, India.
     Int J Tuberc Lung Dis. 2024;28:122-139.
     PubMed     Abstract available
     
     
     
123. SOUSA S, Santos S, Alves CM, Goncalves G, et al
     Impact of annual TB screening on stone quarry workers in high-incidence Portuguese municipalities.
     Int J Tuberc Lung Dis. 2024;28:136-141.
     PubMed     Abstract available
     
     
     
124. THOMSON H, Baines N, Huisamen T, Koegelenberg CFN, et al
     A new understanding of clinical patterns in post-TB lung disease.
     Int J Tuberc Lung Dis. 2024;28:115-121.
     PubMed     Abstract available
     
     
     
125. LEVER S, Akkerman OW, Dekkers BGJ
     Pancreatitis delays the absorption of first-line anti-TB drugs.
     Int J Tuberc Lung Dis. 2024;28:163-165.
     PubMed    
     
     
     
126. YAMKOVOY K, Self JL, Jenkins HE, Horsburgh CR, et al
     Patterns of TB transmission in the United States, 2011-2017.
     Int J Tuberc Lung Dis. 2024;28:154-156.
     PubMed    
     
     
     
127. REZAEE M, Azizi N, Danaei B, Davari A, et al
     TB and interstitial lung disease: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2024;28:130-135.
     PubMed     Abstract available
     
     
     
128. RUDOLF F, Abate E, Moges B, Gomes VF, et al
     A structured 2-week follow-up visit in the cascade of care for TB increases case detection.
     Int J Tuberc Lung Dis. 2024;28:148-153.
     PubMed     Abstract available
     
     
     
129. LEAVITT SV, Rodriguez CA, Bouton TC, Horsburgh CR, et al
     Outcomes for people with TB by disease severity at presentation.
     Int J Tuberc Lung Dis. 2024;28:142-147.
     PubMed     Abstract available
     
     
     February 2024
130. SILVA DR, Santos AP, Visca D, Bombarda S, et al
     The potential for vaccines to aid the treatment of post-TB lung disease.
     Int J Tuberc Lung Dis. 2024;28:44-45.
     PubMed    
     
     
     
131. LONG R, Heffernan C, Lau A
     Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious???
     Int J Tuberc Lung Dis. 2024;28:1-3.
     PubMed    
     
     
     
132. FEKADU G, Wang Y, You JHS
     Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting.
     Int J Tuberc Lung Dis. 2024;28:12-17.
     PubMed     Abstract available
     
     
     
133. TURNER RD, Birring SS, Bothamley GH
     Measuring cough-related quality of life and cough frequency in pulmonary TB.
     Int J Tuberc Lung Dis. 2024;28:25-31.
     PubMed     Abstract available
     
     
     
134. SHIN JE, Jeon D, Mok J, Yim JJ, et al
     Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment.
     Int J Tuberc Lung Dis. 2024;28:18-24.
     PubMed     Abstract available
     
     
     
135. DOLEZALOVA K, Kika V, Wallenfels J
     Increasing incidence of TB in a low burden TB country due to migration from Ukraine.
     Int J Tuberc Lung Dis. 2024;28:39-40.
     PubMed    
     
     
     
136. NIGHTINGALE ES, Feasey HRA, Khundi M, Soko RN, et al
     Community-level variation in TB testing history in Blantyre, Malawi.
     Int J Tuberc Lung Dis. 2024;28:32-38.
     PubMed     Abstract available
     
     
     January 2024
137. YILDIRIM K, Bozkurt S, Basibuyuk HH, Coban AY, et al
     Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.
     Int J Tuberc Lung Dis. 2024;28:37-41.
     PubMed     Abstract available
     
     
     
138. KUMAR SR, Hissar SS, Ramesh PM, Shanmugam M, et al
     Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?
     Int J Tuberc Lung Dis. 2024;28:51-53.
     PubMed    
     
     
     
139. SURIE D, Sathyanarayanan MK, Lavanya J, Smith JP, et al
     Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020.
     Int J Tuberc Lung Dis. 2024;28:54-56.
     PubMed    
     
     
     
140. RICCARDI N, Antonello RM, Besozzi G, Tadolini M, et al
     Ten common myths about drug-susceptible TB.
     Int J Tuberc Lung Dis. 2024;28:61-64.
     PubMed    
     
     
     
141. DU Y, Gu J, Yang Y, Chen Y, et al
     Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury.
     Int J Tuberc Lung Dis. 2024;28:6-12.
     PubMed     Abstract available
     
     
     
142. BEELER ASAY GR, Woodruff R, Sanderson DM, Fisher CF, et al
     Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA.
     Int J Tuberc Lung Dis. 2024;28:21-28.
     PubMed     Abstract available
     
     
     
143. SCHILDKRAUT JA, Sloan D, Boeree MJ
     If you want to go far, go together: standardisation and data sharing in TB drug development.
     Int J Tuberc Lung Dis. 2024;28:3-5.
     PubMed    
     
     
     
144. HOUBEN RMGJ, McCaffrey T, Tiemersma EW, Khan PY, et al
     Estimating TB survival - mind the immortal-time gap.
     Int J Tuberc Lung Dis. 2024;28:65-66.
     PubMed    
     
     
     
145. YUAN S, Cui Y, Shang Y, Su F, et al
     Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018-2021.
     Int J Tuberc Lung Dis. 2024;28:57-58.
     PubMed    
     
     
     
146. GEIGER K, Patil A, Bergman A, Budhathoki C, et al
     Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa.
     Int J Tuberc Lung Dis. 2024;28:42-50.
     PubMed     Abstract available
     
     
     
147. OLIVEIRA DA SILVA B, Salindri AD, Goncalves TO, Cunha EAT, et al
     The impact of sputum quality on Xpert positivity in active case-finding for TB.
     Int J Tuberc Lung Dis. 2024;28:29-36.
     PubMed     Abstract available
     
     
     
148. TYUFEKCHIEVA M, Varleva T
     Monitoring TB infection in contact cases: the impact of the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2024;28:59-60.
     PubMed    
     
     
     December 2023
149. YANG H, Antwi S, Maranchick N, Dompreh A, et al
     Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
     Int J Tuberc Lung Dis. 2023;27:931-937.
     PubMed     Abstract available
     
     
     
150. MAKEK MJ, Trauer JM, Blackbourn HD
     Literature Highlights.
     Int J Tuberc Lung Dis. 2023;27:882-884.
     PubMed     Abstract available
     
     
     
151. ARAUJO-PEREIRA M, Andrade BB
     Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients.
     Int J Tuberc Lung Dis. 2023;27:880-881.
     PubMed    
     
     
     
152. COMMIESIE E, Stijnberg D, van den Boogaard J, Gopie F, et al
     Challenges and opportunities for TB elimination in Suriname.
     Int J Tuberc Lung Dis. 2023;27:946-948.
     PubMed    
     
     
     
153. RAGHEB SM, White JB, Jarand J, Fisher DA, et al
     Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment.
     Int J Tuberc Lung Dis. 2023;27:938-940.
     PubMed    
     
     
     
154. CHUNG C, Jo KW, Shim TS
     Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid.
     Int J Tuberc Lung Dis. 2023;27:918-924.
     PubMed     Abstract available
     
     
     
155. DU CROS P, Greig J, Alffenaar JC, Cross GB, et al
     Standards for clinical trials for treating TB.
     Int J Tuberc Lung Dis. 2023;27:885-898.
     PubMed     Abstract available
     
     
     
156. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
     Atorvastatin improves sputum conversion and chest X-ray severity score.
     Int J Tuberc Lung Dis. 2023;27:912-917.
     PubMed     Abstract available
     
     
     
157. QUINCER EM, Lyland A, Onyango D, LaCourse SM, et al
     The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
     Int J Tuberc Lung Dis. 2023;27:906-911.
     PubMed     Abstract available
     
     
     
158. NETO ERD, Matos TS, Ferreira ACF, Bezerra-Santos M, et al
     The impact of COVID-19 on TB care in Brazil.
     Int J Tuberc Lung Dis. 2023;27:941-943.
     PubMed    
     
     
     
159. MENDOZA-TICONA A, Mitnick CD, Obregon G, Alarcon V, et al
     Screening with GenoType((R)) MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes.
     Int J Tuberc Lung Dis. 2023;27:949-951.
     PubMed    
     
     
     
160. KIBIRIGE D, Andia-Biraro I, Olum R, Adakun S, et al
     Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity.
     Int J Tuberc Lung Dis. 2023;27:944-945.
     PubMed    
     
     
     November 2023
161. EDWARDS S, Humbert T, Berdzuli N, Azzopardi-Muscat N, et al
     Tackling TB in Europe: treatment gaps and deteriorating treatment availability is undermining progress.
     Int J Tuberc Lung Dis. 2023;27:793-796.
     PubMed    
     
     
     
162. MARGINEANU I, Butnaru T, Gafar F, Baiceanu D, et al
     TB therapeutic drug monitoring - analysis of opportunities in Romania and Ukraine.
     Int J Tuberc Lung Dis. 2023;27:816-821.
     PubMed     Abstract available
     
     
     
163. KATRAK S, Wang R, Barry P
     Costs of treating multidrug-resistant TB in California in 2022.
     Int J Tuberc Lung Dis. 2023;27:864-866.
     PubMed    
     
     
     
164. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
     A novel home-based method for preparing suspensions of anti-TB drugs.
     Int J Tuberc Lung Dis. 2023;27:810-815.
     PubMed     Abstract available
     
     
     
165. INBARAJ LR, Rade K, Selvaraju S, Rao R, et al
     Mortality estimates of central nervous system TB in India.
     Int J Tuberc Lung Dis. 2023;27:876-877.
     PubMed    
     
     
     
166. FRITSCHI N, Vaezipour N, Buettcher M, Portevin D, et al
     Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review.
     Int J Tuberc Lung Dis. 2023;27:822-832.
     PubMed     Abstract available
     
     
     October 2023
167. ANDREWS F, Welch S, Scandrett K, Kaur H, et al
     Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK.
     Int J Tuberc Lung Dis. 2023;27:766-771.
     PubMed     Abstract available
     
     
     
168. TRAUER JM, Tiberi S, Graham SM, Blackbourn HD, et al
     Literature Highlights.
     Int J Tuberc Lung Dis. 2023;27:721-723.
     PubMed     Abstract available
     
     
     
169. NELSON KN, Shah NS, Cranmer LM, Vasudevan L, et al
     An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.
     Int J Tuberc Lung Dis. 2023;27:718-720.
     PubMed    
     
     
     
170. PUMA D, Geadas C, Calderon RI, Yuen CM, et al
     Active case-finding for TB among incarcerated women in Peru.
     Int J Tuberc Lung Dis. 2023;27:784-786.
     PubMed    
     
     
     
171. AKKERMAN OW, Dijkwel RDC, Kerstjens HAM, van der Werf TS, et al
     Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
     Int J Tuberc Lung Dis. 2023;27:772-777.
     PubMed     Abstract available
     
     
     
172. CHIANG SS, Zeng C, Roman-Sinche B, Altamirano E, et al
     Adaptation and validation of a TB stigma scale for adolescents in Lima, Peru.
     Int J Tuberc Lung Dis. 2023;27:754-760.
     PubMed     Abstract available
     
     
     
173. KIM JY, Koo B, Lim SY, Cha HH, et al
     A non-invasive, sensitive assay for active TB: combined cell-free DNA detection and FluoroSpot assays.
     Int J Tuberc Lung Dis. 2023;27:790-792.
     PubMed    
     
     
     
174. REKART ML, Aung A, Cullip T, Mulanda W, et al
     Household drug-resistant TB contact tracing in Tajikistan.
     Int J Tuberc Lung Dis. 2023;27:748-753.
     PubMed     Abstract available
     
     
     
175. RAJAVARDHANA T, Koushik MR, Jayakumar C, Ramalingam P, et al
     Adherence to treatment on a daily-dose regimen for TB.
     Int J Tuberc Lung Dis. 2023;27:778-780.
     PubMed    
     
     
     
176. SINGH UB, Ray Y, Kanswal S, Sharma HP, et al
     Low rifampicin levels in plasma associated with a poor clinical response in patients with abdominal TB.
     Int J Tuberc Lung Dis. 2023;27:787-789.
     PubMed    
     
     
     
177. FRAZIER C, Nabity SA, Flood J
     Incidence of TB disease among persons who use drugs in California.
     Int J Tuberc Lung Dis. 2023;27:781-783.
     PubMed    
     
     
     
178. RAJENDRAN P, Saini S, Kumar N, Vashistha H, et al
     Establishing proof of concept for utility of Trueprep((R))-extracted DNA in line-probe assay testing.
     Int J Tuberc Lung Dis. 2023;27:742-747.
     PubMed     Abstract available
     
     
     September 2023
179. MACHAVARIANI E, Nonyane BAS, Lebina L, Mmolawa L, et al
     Perceived stigma among people with TB and household contacts.
     Int J Tuberc Lung Dis. 2023;27:675-681.
     PubMed     Abstract available
     
     
     
180. VILJOEN L, Acaba J, Agbassi YJP, Beko B, et al
     Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.
     Int J Tuberc Lung Dis. 2023;27:655-657.
     PubMed    
     
     
     
181. RODRIGUEZ CA, Leavitt SV, Bouton TC, Horsburgh CR, et al
     Survival of people with untreated TB: effects of time, geography and setting.
     Int J Tuberc Lung Dis. 2023;27:694-702.
     PubMed     Abstract available
     
     
     
182. BECKER GL, Amuge P, Ssebunya R, Motevalli M, et al
     Predictors of mortality in Ugandan children with TB, 2016-2021.
     Int J Tuberc Lung Dis. 2023;27:668-674.
     PubMed     Abstract available
     
     
     
183. DO NASCIMENTO DR, Serpa SF, Bezerra-Santos M, do Carmo RF, et al
     The impact of the COVID-19 pandemic on TB diagnosis in the Brazilian prison population, 2020-2021.
     Int J Tuberc Lung Dis. 2023;27:688-693.
     PubMed     Abstract available
     
     
     
184. GALEA JT, Chu AL, Sweetland AC, Jimenez J, et al
     Latent TB and depressive symptoms in household contacts of persons with active TB.
     Int J Tuberc Lung Dis. 2023;27:682-687.
     PubMed     Abstract available
     
     
     August 2023
185. SILVA DR, Munoz-Torrico M, Fernandes GR, Narvaez-Diaz L, et al
     Isoniazid-resistant TB: treatment outcomes and impact of regimens with fluoroquinolones.
     Int J Tuberc Lung Dis. 2023;27:638-640.
     PubMed    
     
     
     
186. AHMED S, Lotia-Farrukh I, Khan PY, Adnan S, et al
     High prevalence of multidrug-resistant TB among household contacts in a high burden setting.
     Int J Tuberc Lung Dis. 2023;27:646-648.
     PubMed    
     
     
     
187. CHIANG SS, Graham SM, Schaaf HS, Marais BJ, et al
     Clinical standards for drug-susceptible TB in children and adolescents.
     Int J Tuberc Lung Dis. 2023;27:584-598.
     PubMed     Abstract available
     
     
     
188. MAKEK MJ, Amorim GGC, Ragonnet R, Blackbourn HD, et al
     Literature Highlights.
     Int J Tuberc Lung Dis. 2023;27:581-583.
     PubMed     Abstract available
     
     
     
189. ACUNA-VILLAORDUNA C, Jacobson KR, Horsburgh CR, Canning M, et al
     Initial experience with BPaL-based regimens to treat multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:649-650.
     PubMed    
     
     
     
190. HACKER B, Breuer C, Priwitzer M, Otto-Knapp R, et al
     TB screening of Ukrainian refugees in Germany.
     Int J Tuberc Lung Dis. 2023;27:641-642.
     PubMed    
     
     
     
191. HONGPRASIT P, Sonthisombat P
     Assessment of TB treatment adherence using computer-assisted self-interviewing.
     Int J Tuberc Lung Dis. 2023;27:626-631.
     PubMed     Abstract available
     
     
     
192. RIKHOTSO MC, Ledwaba SE, Ngandu JK, Mavumengwana V, et al
     Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
     Int J Tuberc Lung Dis. 2023;27:599-605.
     PubMed     Abstract available
     
     
     
193. MARITZ ER, Montepiedra G, Mitchell CD, Madhi SA, et al
     Predictors of TB disease in HIV-exposed children from Southern Africa.
     Int J Tuberc Lung Dis. 2023;27:619-625.
     PubMed     Abstract available
     
     
     
194. CHIBOLELA M, de Haas P, Klinkenberg E, Kosloff B, et al
     Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.
     Int J Tuberc Lung Dis. 2023;27:612-618.
     PubMed     Abstract available
     
     
     
195. HABIB SS, Uzair M, Dhanwani A, Sohail K, et al
     A model for integrating social protection measures with TB control in Pakistan.
     Int J Tuberc Lung Dis. 2023;27:651-652.
     PubMed    
     
     
     
196. RACHOW A, Ivanova O, Bakuli A, Khosa C, et al
     Performance of spirometry assessment at TB diagnosis.
     Int J Tuberc Lung Dis. 2023;27:850-857.
     PubMed     Abstract available
     
     
     
197. SALERNO MM, Burzynski J, Mangan JM, Hill A, et al
     Adverse events among persons with TB using in-person vs. electronic directly observed therapy.
     Int J Tuberc Lung Dis. 2023;27:833-840.
     PubMed     Abstract available
     
     
     
198. OWOLABI OA, Sillah AK, Loum I, Touray A, et al
     Factors associated with presenting to private sector care providers at the onset of TB symptoms.
     Int J Tuberc Lung Dis. 2023;27:867-868.
     PubMed    
     
     
     
199. SILVESTRE CR, Cavaco M, Afonso R, Alves S, et al
     TB infection in healthcare workers - the reality of a Portuguese hospital.
     Int J Tuberc Lung Dis. 2023;27:874-875.
     PubMed    
     
     
     
200. CHO MM, Kim HW, Kim JS, Min J, et al
     TB in ageing populations: lessons from Japan and Korea.
     Int J Tuberc Lung Dis. 2023;27:869-871.
     PubMed    
     
     
     July 2023
201. NUR N, Sharif AB, Mitra DK
     Stress resilience in patients with drug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:551-556.
     PubMed     Abstract available
     
     
     
202. OKOYA F, Huang CC, Zhang Z, Lecca L, et al
     Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.
     Int J Tuberc Lung Dis. 2023;27:557-563.
     PubMed     Abstract available
     
     
     
203. ESCALANTE P, Vadiyala MR, Pathakumari B, Marty PK, et al
     New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease.
     Int J Tuberc Lung Dis. 2023;27:499-505.
     PubMed     Abstract available
     
     
     
204. STRAUSS M, Wademan DT, Mcinziba A, Hoddinott G, et al
     TB preventive therapy preferences among children and adolescents.
     Int J Tuberc Lung Dis. 2023;27:520-529.
     PubMed     Abstract available
     
     
     
205. HARRIES AD, Lin Y, Thekkur P, Nair D, et al
     Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.
     Int J Tuberc Lung Dis. 2023;27:495-498.
     PubMed    
     
     
     
206. GLOGOWSKA A, Przybylski G, Bukowski J, Dolska E, et al
     TB and COVID-19 co-infection in a pulmonology hospital.
     Int J Tuberc Lung Dis. 2023;27:574-576.
     PubMed    
     
     
     
207. FERRARESE M, Antonello RM, Torri S, Saderi L, et al
     Extrapulmonary TB: a 30-year observational study of an Italian cohort.
     Int J Tuberc Lung Dis. 2023;27:564-566.
     PubMed    
     
     
     
208. WADEMAN DT, Viljoen L, Jacobs S, Meyerson K, et al
     Children s priorities to improve the acceptability of MDR-TB treatment: qualitative data from South Africa.
     Int J Tuberc Lung Dis. 2023;27:543-550.
     PubMed     Abstract available
     
     
     
209. SINGH KP, Carvalho ACC, Centis R, D Ambrosio L, et al
     Clinical standards for the management of adverse effects during treatment for TB.
     Int J Tuberc Lung Dis. 2023;27:506-519.
     PubMed     Abstract available
     
     
     
210. MARQUES J, Rocha JV, Soares P, Leite A, et al
     The effect of TB patient delay on loss to follow-up in Portugal.
     Int J Tuberc Lung Dis. 2023;27:537-542.
     PubMed     Abstract available
     
     
     
211. CENTENO HURTADO KT, Garcia Bohorquez DF, Ruiz Gonzalez CE, Masias Leon Y, et al
     The burden of chronic obstructive pulmonary disease among hospitalised women in a developing country.
     Int J Tuberc Lung Dis. 2023;27:530-536.
     PubMed     Abstract available
     
     
     
212. VENGURLEKAR D, Walker C, Mahajan R, Dalal A, et al
     Linezolid resistance in patients with drug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:567-569.
     PubMed    
     
     
     
213. ZUREIGAT H, Alhusban M, Nawaiseh M, Alomari L, et al
     Steps towards TB elimination in Jordan.
     Int J Tuberc Lung Dis. 2023;27:576-577.
     PubMed    
     
     
     June 2023
214. DE VRIES G, Akkerman O, Boeree M, van Hest R, et al
     Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019.
     Int J Tuberc Lung Dis. 2023;27:471-477.
     PubMed     Abstract available
     
     
     
215. MALHOTRA A, Mukiibi J, Kitonsa PJ, Nalutaaya A, et al
     Higher yield using an event-based vs. door-to-door approach for active case-finding for TB.
     Int J Tuberc Lung Dis. 2023;27:484-486.
     PubMed    
     
     
     
216. MAKEK MJ, Tiberi S, Felker I, Amorim GGC, et al
     Literature Highlights.
     Int J Tuberc Lung Dis. 2023;27:429-431.
     PubMed     Abstract available
     
     
     
217. NI N, Wang N, Veronese V, Wang MZ, et al
     Current status and future prospects of TB digital treatment adherence technology use in China.
     Int J Tuberc Lung Dis. 2023;27:438-443.
     PubMed     Abstract available
     
     
     
218. KIM SH, Yoo JY, Cho HS, Kim SR, et al
     Clinical and imaging features of drug-susceptible and multidrug-resistant TB in Korean adults.
     Int J Tuberc Lung Dis. 2023;27:487-489.
     PubMed    
     
     
     
219. LOUIE JK, Keh C, Agraz-Lara R, Phillips A, et al
     Highlighting the characteristics of TB disease in older people.
     Int J Tuberc Lung Dis. 2023;27:478-480.
     PubMed    
     
     
     
220. SUNG J, Musinguzi A, Kadota JL, Baik Y, et al
     Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
     Int J Tuberc Lung Dis. 2023;27:458-464.
     PubMed     Abstract available
     
     
     
221. OESER C, Rangaka MX, Abubakar I
     Digital approaches to reducing TB treatment loss to follow-up.
     Int J Tuberc Lung Dis. 2023;27:432-437.
     PubMed     Abstract available
     
     
     
222. RICH ML, Khan U, Zeng C, LaHood A, et al
     Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
     Int J Tuberc Lung Dis. 2023;27:451-457.
     PubMed     Abstract available
     
     
     
223. MYERS B, Carney T, Rooney J, Malatesta S, et al
     Smoked drug use in patients with TB is associated with higher bacterial burden.
     Int J Tuberc Lung Dis. 2023;27:444-450.
     PubMed     Abstract available
     
     
     
224. OTAALO B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, et al
     Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
     Int J Tuberc Lung Dis. 2023;27:481-483.
     PubMed    
     
     
     May 2023
225. GUNTHER G, Guglielmetti L, Leu C, van Leth F, et al
     Relative cost of multidrug-resistant TB medicines in Europe.
     Int J Tuberc Lung Dis. 2023;27:341-344.
     PubMed    
     
     
     
226. KWARA A, Yang H, Martyn-Dickens C, Enimil A, et al
     Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
     Int J Tuberc Lung Dis. 2023;27:401-407.
     PubMed     Abstract available
     
     
     
227. GIRIDHARAN P, Devaleenal B, Thiruvengadam K, Kaleeswari M, et al
     A novel method for contact tracing for TB at household and community level.
     Int J Tuberc Lung Dis. 2023;27:414-415.
     PubMed    
     
     
     
228. SADERI L, Cabibbe AM, Puci M, Di Lorenzo B, et al
     A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings.
     Int J Tuberc Lung Dis. 2023;27:348-356.
     PubMed     Abstract available
     
     
     
229. GERIC C, Qin ZZ, Denkinger CM, Kik SV, et al
     The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination.
     Int J Tuberc Lung Dis. 2023;27:367-372.
     PubMed     Abstract available
     
     
     
230. FAJER EB, Costa FD, Pelissari DM, Diaz Quijano FA, et al
     Use of rapid molecular TB diagnostics for incarcerated people in Brazil.
     Int J Tuberc Lung Dis. 2023;27:416-418.
     PubMed    
     
     
     
231. KASWASWA K, Mlauzi L, Mpunga J, Mandambwe C, et al
     Use of local data to evaluate TB contact investigation in Malawi.
     Int J Tuberc Lung Dis. 2023;27:408-410.
     PubMed    
     
     
     
232. TANG J, Tang Z, Feng C, Tang Q, et al
     Efficacy and safety of video-assisted thoracoscopic surgery for pulmonary TB.
     Int J Tuberc Lung Dis. 2023;27:387-394.
     PubMed     Abstract available
     
     
     
233. MAUGANS C, Loveday M, Hlangu S, Waitt C, et al
     Best practices for the care of pregnant people living with TB.
     Int J Tuberc Lung Dis. 2023;27:357-366.
     PubMed     Abstract available
     
     
     
234. TAGUIBAO C, Lailo JM, Neukom J, Gones V, et al
     Digital survey results on pharmacy access to fixed-dose combination drugs for TB in Indonesia.
     Int J Tuberc Lung Dis. 2023;27:422-424.
     PubMed    
     
     
     
235. MOE S, Rekart ML, Hernandez D, Sholpan A, et al
     Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
     Int J Tuberc Lung Dis. 2023;27:381-386.
     PubMed     Abstract available
     
     
     
236. AHMED R, Osman N, Noory B, Osman R, et al
     Prevalence and determinants of chronic respiratory diseases in adults in Sudan.
     Int J Tuberc Lung Dis. 2023;27:373-380.
     PubMed     Abstract available
     
     
     
237. PAREDES JL, Picon V, Reynolds L, Ugarte-Gil C, et al
     Impact of the COVID-19 pandemic on TB care in Peru.
     Int J Tuberc Lung Dis. 2023;27:411-413.
     PubMed    
     
     
     
238. MUTEMBA CM, Schindele A, Munyangaju I, Ramanlal N, et al
     Contribution of Xpert((R)) MTB/RIF to pediatric TB diagnosis in Mozambique.
     Int J Tuberc Lung Dis. 2023;27:419-421.
     PubMed    
     
     
     April 2023
239. GRIJOTA-CAMINO MD, Perez-Recio S, Trapero C, Luque MJ, et al
     Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting.
     Int J Tuberc Lung Dis. 2023;27:315-321.
     PubMed     Abstract available
     
     
     
240. VELEN K, Nguyen TA, Pham CD, Le HT, et al
     The effect of medication event reminder monitoring on treatment adherence of TB patients.
     Int J Tuberc Lung Dis. 2023;27:322-328.
     PubMed     Abstract available
     
     
     
241. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, van Boven JFM, et al
     Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials.
     Int J Tuberc Lung Dis. 2023;27:335-337.
     PubMed    
     
     
     
242. GOLETTI D, Pisapia R, Fusco FM, Aiello A, et al
     Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes.
     Int J Tuberc Lung Dis. 2023;27:284-290.
     PubMed     Abstract available
     
     
     
243. MIGLIORI GB, Blackbourn HD
     Post-TB lung disease - the rationale for a Clinical Statement.
     Int J Tuberc Lung Dis. 2023;27:243-244.
     PubMed    
     
     
     
244. CAMPBELL JR, Chan ED, Anderson LF, Bonnet M, et al
     Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes.
     Int J Tuberc Lung Dis. 2023;27:338-340.
     PubMed    
     
     
     
245. SACHDEVA KS, Bhatnagar AK, Bhaskar A, Singla N, et al
     QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting.
     Int J Tuberc Lung Dis. 2023;27:329-331.
     PubMed    
     
     
     
246. KAZIBWE A, Kyazze AP, Ssekamatte P, Mutebi EI, et al
     TB infection in adults with diabetes mellitus in Uganda.
     Int J Tuberc Lung Dis. 2023;27:308-314.
     PubMed     Abstract available
     
     
     
247. NIGHTINGALE R, Carlin F, Meghji J, McMullen K, et al
     Post-TB health and wellbeing.
     Int J Tuberc Lung Dis. 2023;27:248-283.
     PubMed     Abstract available
     
     
     
248. MANGAN JM, Burzynski J, deCastro BR, Salerno MM, et al
     Challenges associated with electronic and in-person directly observed therapy during a randomized trial.
     Int J Tuberc Lung Dis. 2023;27:298-307.
     PubMed     Abstract available
     
     
     
249. KINTU TM, Mwanahamisi BS, Muwanguzi M, Kyagambiddwa T, et al
     Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda.
     Int J Tuberc Lung Dis. 2023;27:291-297.
     PubMed     Abstract available
     
     
     March 2023
250. COLA JP, Nascimento do Prado T, Alves KBA, Lapa E Silva JR, et al
     Factors associated with non-completion of TB preventive treatment in Brazil.
     Int J Tuberc Lung Dis. 2023;27:215-220.
     PubMed     Abstract available
     
     
     
251. HUDDART S, Asege L, Jaganath D, Golla M, et al
     Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring.
     Int J Tuberc Lung Dis. 2023;27:221-222.
     PubMed    
     
     
     
252. YAACOUB H, Farhat AM, Najjar-Pellet J, Zgheib J, et al
     Planning for TB elimination in Lebanon.
     Int J Tuberc Lung Dis. 2023;27:171-174.
     PubMed    
     
     
     
253. KWON YS, Jang JG, Lee J, Choi KJ, et al
     Risk factors for peripheral neuropathy in patients on linezolid-containing regimens for drug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:232-234.
     PubMed    
     
     
     
254. PALACIOS CF, Hough MA, Shrestha R, Moll AP, et al
     Perceived stigma related to TB preventive therapy.
     Int J Tuberc Lung Dis. 2023;27:209-214.
     PubMed     Abstract available
     
     
     
255. AKKERMAN OW, van Het Hof S, de Vries G, van Crevel R, et al
     Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TB.
     Int J Tuberc Lung Dis. 2023;27:237-239.
     PubMed    
     
     
     
256. HUAROTO L, Huaman MA, Mugruza R, Ticona C, et al
     Active case-finding of pulmonary TB in an urban emergency department.
     Int J Tuberc Lung Dis. 2023;27:202-208.
     PubMed     Abstract available
     
     
     
257. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
     Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial.
     Int J Tuberc Lung Dis. 2023;27:226-228.
     PubMed    
     
     
     
258. MALIK AA, Jaswal M, Siddiqui S, Amanullah F, et al
     Role of symptom and chest X-ray screening in evaluating child household contacts for pulmonary TB.
     Int J Tuberc Lung Dis. 2023;27:235-236.
     PubMed    
     
     
     
259. TRAUER JM
     Targeted TB control in migrants to low-burden countries.
     Int J Tuberc Lung Dis. 2023;27:169-170.
     PubMed    
     
     
     
260. MARTINEZ-GARCIA MA, Guan WJ, de-la-Rosa D, Athanazio R, et al
     Post-TB bronchiectasis: from pathogenesis to rehabilitation.
     Int J Tuberc Lung Dis. 2023;27:175-181.
     PubMed     Abstract available
     
     
     
261. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
     Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.
     Int J Tuberc Lung Dis. 2023;27:189-194.
     PubMed     Abstract available
     
     
     
262. DAMARAJU V, Singh N, Garg M, Kathirvel S, et al
     Effect of prior pulmonary TB on low-dose computed tomography during lung cancer screening.
     Int J Tuberc Lung Dis. 2023;27:223-225.
     PubMed    
     
     
     
263. SPRUIJT I, Erkens C, Greenaway C, Mulder C, et al
     Reducing the burden of TB among migrants to low TB incidence countries.
     Int J Tuberc Lung Dis. 2023;27:182-188.
     PubMed     Abstract available
     
     
     
264. BAIK Y, Nakasolya O, Isooba D, Mukiibi J, et al
     Cost to perform door-to-door universal sputum screening for TB in a high-burden community.
     Int J Tuberc Lung Dis. 2023;27:195-201.
     PubMed     Abstract available
     
     
     February 2023
265. CHUNG C, Shin JE, Jeon D, Kang H, et al
     Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:151-153.
     PubMed    
     
     
     
266. GOMES I, Garg T, Churchyard G, Gupta A, et al
     The cascade of care for household contacts of people with drug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:154-156.
     PubMed    
     
     
     
267. TOCHAENG C, Eksombatchai D, Boonsarngsuk V
     Factors associated with false-negative for T-SPOT.TB in patients with TB disease.
     Int J Tuberc Lung Dis. 2023;27:128-134.
     PubMed     Abstract available
     
     
     
268. ALKABAB Y, Warkentin J, Cummins J, Katz B, et al
     Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus.
     Int J Tuberc Lung Dis. 2023;27:135-139.
     PubMed     Abstract available
     
     
     
269. FORSMAN LD, Alffenaar JWC
     Diabetes mellitus and TB - finding strategies to reduce the double burden of disease.
     Int J Tuberc Lung Dis. 2023;27:91-93.
     PubMed    
     
     
     
270. BARKER M, Gunther A, Wurps H, Gebhardt A, et al
     Ultrasound-guided lymph node biopsy in smear-negative children and adolescents with suspected TB.
     Int J Tuberc Lung Dis. 2023;27:164-165.
     PubMed    
     
     
     
271. BOLSTERLI E, Keller PM, Suter-Riniker F, Kruger L, et al
     A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB.
     Int J Tuberc Lung Dis. 2023;27:148-150.
     PubMed    
     
     
     
272. VILLA S, Carugati M, Rubach MP, Cleaveland S, et al
     'One Health approach to end zoonotic TB.
     Int J Tuberc Lung Dis. 2023;27:101-105.
     PubMed     Abstract available
     
     
     
273. BALTAS I, Sturdy A, Kavallieros K, McGregor A, et al
     Diabetes mellitus is not a predictor of poor TB treatment outcomes.
     Int J Tuberc Lung Dis. 2023;27:140-145.
     PubMed     Abstract available
     
     
     
274. CHUKWUOGO O, Odume B, Ogbudebe C, Useni S, et al
     Strategic approach to optimisation of TB contact investigation in Nigeria.
     Int J Tuberc Lung Dis. 2023;27:161-163.
     PubMed    
     
     
     
275. PAUDEL K, Nalutaaya A, Robsky KO, Kitonsa PJ, et al
     The impact of time at home on potential yield of home-based TB contact investigation.
     Int J Tuberc Lung Dis. 2023;27:121-127.
     PubMed     Abstract available
     
     
     
276. KOESOEMADINATA RC, McAllister SM, Soetedjo NNM, Santoso P, et al
     Diabetes characteristics and long-term management needs in diabetic TB patients.
     Int J Tuberc Lung Dis. 2023;27:113-120.
     PubMed     Abstract available
     
     
     
277. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
     Extemporaneously compounded liquid formulations of clofazimine.
     Int J Tuberc Lung Dis. 2023;27:106-112.
     PubMed     Abstract available
     
     
     
278. GENADE LP, Kahamba T, Scott L, Tempia S, et al
     Co-testing a single sputum specimen for TB and SARS-CoV-2.
     Int J Tuberc Lung Dis. 2023;27:146-147.
     PubMed    
     
     
     January 2023
279. KHAN U, Guglielmetti L
     Tailored TPT for drug-resistant TB - promoting equity and access to optimal care.
     Int J Tuberc Lung Dis. 2023;27:89b-90.
     PubMed    
     
     
     
280. MANSOOR H, Hirani N, Chavan V, Das M, et al
     Clinical utility of target-based next-generation sequencing for drug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:41-48.
     PubMed     Abstract available
     
     
     
281. GILLESPIE SH
     Improving outcomes for multidrug-resistant TB: the role of integrated systems.
     Int J Tuberc Lung Dis. 2023;27:1-2.
     PubMed    
     
     
     
282. SEHGAL IS, Muthu V, Agarwal R
     Aspergillus infection is an important complication of post-TB bronchiectasis.
     Int J Tuberc Lung Dis. 2023;27:89a-89.
     PubMed    
     
     
     
283. OLARU ID, Beliz Meier M, Schumacher SG, Prodanovic N, et al
     Co-administration of treatment for drug-resistant TB and hepatitis C.
     Int J Tuberc Lung Dis. 2023;27:66-68.
     PubMed    
     
     
     
284. FELKER I, Trajman A
     Shorter regimens for multidrug-/rifampicin-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:3-4.
     PubMed    
     
     
     
285. KWON YS, Shin JE, Kang H, Jeon D, et al
     Treatment outcomes of multidrug-resistant TB with selective use of new drugs.
     Int J Tuberc Lung Dis. 2023;27:55-60.
     PubMed     Abstract available
     
     
     
286. ZENG C, Mitnick CD, Hewison C, Bastard M, et al
     Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:34-40.
     PubMed     Abstract available
     
     
     
287. CANTERA JL, Rashid AA, Lillis LM, Peck RB, et al
     Isolation and purification of lipoarabinomannan from urine of adults with active TB.
     Int J Tuberc Lung Dis. 2023;27:75-77.
     PubMed    
     
     
     
288. KNUDSEN S, Babu SP, Ramakrishnan J, Jenkins HE, et al
     M. tuberculosis infection before, during and after pregnancy.
     Int J Tuberc Lung Dis. 2023;27:72-74.
     PubMed    
     
     
     
289. ATSHEMYAN H, Khachatryan N, Manukyan A, Khachatryan A, et al
     Implementation of modified, all-oral shorter TB regimens in Armenia.
     Int J Tuberc Lung Dis. 2023;27:84-85.
     PubMed    
     
     
     
290. BUTOV D, Feshchenko Y, Chesov D, Myasoedov V, et al
     National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022.
     Int J Tuberc Lung Dis. 2023;27:86-88.
     PubMed    
     
     
     
291. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
     Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB.
     Int J Tuberc Lung Dis. 2023;27:13-18.
     PubMed     Abstract available
     
     
     
292. MAH JK, Lieu A, Fisher D, Lim RK, et al
     Impact of the COVID-19 pandemic on the epidemiology of TB in a low-incidence setting.
     Int J Tuberc Lung Dis. 2023;27:69-71.
     PubMed    
     
     
     
293. COX SR, Padmapriyadarsini C, Mave V, Seth B, et al
     Characterising cause of death among people treated for drug-susceptible TB in India.
     Int J Tuberc Lung Dis. 2023;27:78-80.
     PubMed    
     
     
     
294. JAW-TSAI S, Barry R, Pande PG, Taneja R, et al
     Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs.
     Int J Tuberc Lung Dis. 2023;27:28-33.
     PubMed     Abstract available
     
     
     
295. DE HAAS P, Nhung NV, Hng NT, Hoa NB, et al
     Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults.
     Int J Tuberc Lung Dis. 2023;27:19-27.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.